ArticleCase reports in critical care2025
Acute Type A Aortic Dissection During Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor Lenvatinib Therapy.
Article in Case reports in critical care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Acute Aortic Dissection Associated With Cancer Therapy in a Previously Normal Aorta.JACC. Case reports · 2026Article
- Aortic dissection as a disease of vascular wall homeostasis: integrating vasa vasorum-inflammation-metabolism axis for mechanistic insight and clinical translation.Frontiers in immunology · 2026Review
- Acute Type A Aortic Dissection During Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor Lenvatinib Therapy.Case reports in critical care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 67-year-old male with hepatocellular carcinoma under lenvatinib therapy suffered from initially back pain and then abdominal pain, dyspnea, and oliguria. Acute type A aortic dissection was diagnosed with point-of-care ultrasound and computed tomography during the admission. Patients treated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have a low but significant risk of aortic dissection. As a newer member of VEGF-TKIs, lenvatinib has a similar or even higher risk of aortic dissection compared to others. Clinicians should take the cardiovascular risk into consideration while prescribing lenvatinib and keep the differential diagnosis of aortic dissection in mind during the therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.